Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | LCK | P06239 | 1/20 | 0.53 |
| ▸ | PPARD | Q03181 | 1/20 | 0.53 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.53 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.53 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL308689 | 1.00 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL5530871 | 1.00 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL7006048 | 1.00 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL18221941 | 1.00 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL351779 | 1.00 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL871399 | 1.00 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2854830 | 1.00 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL2015722 | 1.00 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL6930290 | 1.00 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD | |
| SCHEMBL3852448 | 1.00 | GPR84 (0.55) | GPR84FFAR1MAPTLCKPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10632086-B2 | Methods and compositions for treating Raynaud's disease | NEXMED HOLDINGS, INC. (US) | 2020-04-28 | — | — | US | claimed |
| US-20180333377-A1 | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE | NEXMED HOLDINGS, INC. (US) | 2018-11-22 | — | — | US | claimed |
| US-9682068-B2 | Transdermal therapeutic system for extended dosing of pramipexole in treating neurological disorders | MYLAN INC. (US) | 2017-06-20 | — | — | US | claimed |
| US-20160113908-A1 | Transdermal Therapeutic System for Extended Dosing of Pramipexole in Treating Neurological Disorders | MYLAN INC. | 2016-04-28 | — | — | US | claimed |
| EP-2999444-A2 | TRANSDERMAL EXTENDED DOSING OF PRAMIPEXOLE FOR NEUROLOGICAL DISORDERS | Mylan Inc. (US) | 2016-03-30 | — | — | EP | claimed |
| EP-2693877-A1 | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE | NexMed Holdings, Inc. (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2012139033-A1 | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE | NEXMED HOLDINGS, INC. (US) | 2012-10-11 | — | — | WO | claimed |
| EP-1585483-B1 | TOPICAL STABILIZED PROSTAGLANDIN E COMPOUND DOSAGE FORMS | NEXMED HOLDINGS INC (US) | 2010-05-19 | — | — | EP | claimed |
| US-20090175928-A1 | Lip Plaster | LABTEC GESELLSCHAFT FUR TECHNOLOGISCHE FORSCHUNG UND ENTWICKLUNG MBH (DE) | 2009-07-09 | — | — | US | claimed |
| US-20080279915-A1 | Matrix-Controlled Transdermal Therapeutic System Based on an Adhesive for Administering Norelgestromin or the Combination Thereof with an Estrogen | HEXAL AG (DE) | 2008-11-13 | — | — | US | claimed |
| WO-2025062440-A1 | TOPICAL NANO-DISPERSION COMPOSITIONS AND THEIR PREPARATION THEREOF | PULSE PHARMACEUTICALS PVT. LTD (IN) | 2025-03-27 | — | — | WO | disclosed |
| US-20240226126-A1 | COMPOSITIONS FOR TREATMENT OF PSORIASIS | BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY, THE | 2024-07-11 | — | — | US | disclosed |
| CN-111587243-B | Method for solubilising 5-amino-2, 3-dihydro-1, 4-phthalazinediones | 麦翠奥制药公司 | 2024-04-12 | — | — | CN | disclosed |
| US-11730705-B2 | Small molecule CMKLR1 antagonists in inflammatory disease | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-08-22 | — | — | US | disclosed |
| WO-2022266251-A9 | COMPOSITIONS FOR TREATMENT OF PSORIASIS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2005046600-A2 | TRANSDERMAL TULOBUTEROL DELIVERY | NEXMED HOLDINGS, INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20040253299-A1 | Transdermal therapeutic system (reservoir-tts) for using pramipexole and ropinirole | HEXAL AG (DE) | 2004-12-16 | — | — | US | disclosed |
| US-20040247656-A1 | Matrix controlled transdermal therapeutic system for the use of pramipexole and ropinirole | HEXAL AG (DE) | 2004-12-09 | — | — | US | disclosed |
| US-20040086552-A1 | Transdermal therapeutic system for highly dispersed silicon dioxide | HEXAL AG (DE) | 2004-05-06 | — | — | US | disclosed |
| US-20040047901-A1 | Storage stability | HEXAL AG (DE) | 2004-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160113908-A1 | Transdermal Therapeutic System for Extended Dosing of Pramipexole in Treating Neurological Disorders | ACHE, TES, ADAMTS5 | GPR84 1955/4885FFAR1 3899/4885MAPT 16/4885 |
| US-11730705-B2 | Small molecule CMKLR1 antagonists in inflammatory disease | CMKLR1, CMKLR2, IL1RN | GPR84 523/4885FFAR1 681/4885MAPT 902/4885 |
| US-20180333377-A1 | METHODS AND COMPOSITIONS FOR TREATING RAYNAUD'S DISEASE | PTGER1, PTGES, PTGS1 | GPR84 1783/4885FFAR1 866/4885MAPT 4043/4885 |
| US-10632086-B2 | Methods and compositions for treating Raynaud's disease | PTGER1, PTGES, PTGS1 | GPR84 1783/4885FFAR1 866/4885MAPT 4043/4885 |
| US-20240226126-A1 | COMPOSITIONS FOR TREATMENT OF PSORIASIS | S100A4, RORC, IL17A | GPR84 1412/4885FFAR1 1914/4885MAPT 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.